Jain R, Epstein J
Adv Exp Med Biol. 2024; 1441:341-364.
PMID: 38884720
DOI: 10.1007/978-3-031-44087-8_18.
Potapenko A, Davidson J, Lee A, Laird A
Biochem J. 2024; 481(6):461-480.
PMID: 38497605
PMC: 11088879.
DOI: 10.1042/BCJ20240017.
Zhang L, Zhu B, Zhou X, Ning H, Zhang F, Yan B
Neurotox Res. 2024; 42(1):12.
PMID: 38329647
DOI: 10.1007/s12640-024-00693-4.
Xie S, Duan C
aBIOTECH. 2023; 4(2):124-139.
PMID: 37581024
PMC: 10423193.
DOI: 10.1007/s42994-023-00101-z.
Han Y, Haouel A, Georgii E, Priego-Cubero S, Wurm C, Hemmler D
Genes (Basel). 2023; 14(6).
PMID: 37372378
PMC: 10298649.
DOI: 10.3390/genes14061199.
Ovulatory signal-triggered chromatin remodeling in ovarian granulosa cells by HDAC2 phosphorylation activation-mediated histone deacetylation.
Jin J, Ren P, Li X, Zhang Y, Yang W, Ma Y
Epigenetics Chromatin. 2023; 16(1):11.
PMID: 37076890
PMC: 10116676.
DOI: 10.1186/s13072-023-00485-8.
Epigenetic Regulation Mediated by Sphingolipids in Cancer.
Bozzini N, Avnet S, Baldini N, Cortini M
Int J Mol Sci. 2023; 24(6).
PMID: 36982369
PMC: 10048860.
DOI: 10.3390/ijms24065294.
Epicardial HDAC3 Promotes Myocardial Growth Through a Novel MicroRNA Pathway.
Jang J, Song G, Pettit S, Li Q, Song X, Cai C
Circ Res. 2022; 131(2):151-164.
PMID: 35722872
PMC: 9308743.
DOI: 10.1161/CIRCRESAHA.122.320785.
Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors.
Ushio R, Hiroi M, Matsumoto A, Mori K, Yamamoto N, Ohmori Y
Biomedicines. 2022; 10(4).
PMID: 35453513
PMC: 9029187.
DOI: 10.3390/biomedicines10040763.
Structural mass spectrometry decodes domain interaction and dynamics of the full-length Human Histone Deacetylase 2.
Soloviev Z, Bullock J, James J, Sauerwein A, Nettleship J, Owens R
Biochim Biophys Acta Proteins Proteom. 2022; 1870(3):140759.
PMID: 35051665
PMC: 8825994.
DOI: 10.1016/j.bbapap.2022.140759.
Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma.
Xie J, Wang Z, Fan W, Liu Y, Liu F, Wan X
Signal Transduct Target Ther. 2021; 6(1):333.
PMID: 34482361
PMC: 8418605.
DOI: 10.1038/s41392-021-00702-4.
Chemo-proteomics exploration of HDAC degradability by small molecule degraders.
Xiong Y, Donovan K, Eleuteri N, Kirmani N, Yue H, Razov A
Cell Chem Biol. 2021; 28(10):1514-1527.e4.
PMID: 34314730
PMC: 9339248.
DOI: 10.1016/j.chembiol.2021.07.002.
Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure.
Wang N, Peng Y, Su X, Prabhakar N, Nanduri J
Front Physiol. 2021; 12:688322.
PMID: 34079475
PMC: 8165245.
DOI: 10.3389/fphys.2021.688322.
HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
Ha S, Lewin N, Li S, Kim S
Cells. 2021; 10(5).
PMID: 34064422
PMC: 8147860.
DOI: 10.3390/cells10051101.
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
Garmpis N, Damaskos C, Garmpi A, Georgakopoulou V, Sarantis P, Antoniou E
J Pers Med. 2021; 11(3).
PMID: 33809844
PMC: 8004277.
DOI: 10.3390/jpm11030223.
MiR-520d-5p modulates chondrogenesis and chondrocyte metabolism through targeting HDAC1.
Lu J, Zhou Z, Sun B, Han B, Fu Q, Han Y
Aging (Albany NY). 2020; 12(18):18545-18560.
PMID: 32950972
PMC: 7585120.
DOI: 10.18632/aging.103831.
Role of histone deacetylases in bone development and skeletal disorders.
Wang J, Yoon S, Wein M
Bone. 2020; 143:115606.
PMID: 32829038
PMC: 7770092.
DOI: 10.1016/j.bone.2020.115606.
Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R, Toor S, Sasidharan Nair V, Elkord E
Front Immunol. 2020; 11:1469.
PMID: 32760400
PMC: 7371937.
DOI: 10.3389/fimmu.2020.01469.
HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo.
Sanna S, Esposito S, Masala A, Sini P, Nieddu G, Galioto M
Cell Death Dis. 2020; 11(5):369.
PMID: 32409664
PMC: 7224392.
DOI: 10.1038/s41419-020-2580-3.
Monocarboxylate Transporter 4 Regulates Glioblastoma Motility and Monocyte Binding Ability.
Lai S, Lin H, Liu Y, Yang L, Lu D
Cancers (Basel). 2020; 12(2).
PMID: 32045997
PMC: 7073205.
DOI: 10.3390/cancers12020380.